Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | CKS1B | P61024 | 1/20 | 0.50 |
| ▸ | SKP1 | P63208 | 1/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.50 |
| ▸ | TRPC6 | Q9Y210 | 2/20 | 0.49 |
| ▸ | WNT3A | P56704 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.47 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1393764 | 1.00 | MAPT (0.56) | MAPTALDH1A1LMNAGPR119MEN1 | |
| Ammonia Solution, Strong SCHEMBL28415331 | 0.99 | GPR119 (0.55) | MAPTALDH1A1LMNAGPR119MEN1 | |
| SCHEMBL29437363 | 0.99 | GPR119 (0.55) | MAPTALDH1A1LMNAGPR119MEN1 | |
| SCHEMBL26641577 | 0.99 | MAPT (0.58) | MAPTALDH1A1LMNAGPR119MEN1 | |
| SCHEMBL30316131 | 0.95 | CKS1B (0.53) | MAPTALDH1A1LMNAGPR119MEN1 | |
| SCHEMBL1990159 | 0.95 | CKS1B (0.53) | MAPTALDH1A1LMNAGPR119MEN1 | |
| SCHEMBL26641386 | 0.93 | GPR119 (0.52) | MAPTALDH1A1LMNAGPR119MEN1 | |
| SCHEMBL30643550 | 0.93 | GPR119 (0.52) | MAPTALDH1A1LMNAGPR119MEN1 | |
| SCHEMBL28767159 | 0.90 | MAP4K4 (0.51) | MAPTALDH1A1LMNAGPR119MEN1 | |
| SCHEMBL23783349 | 0.89 | GPR119 (0.67) | MAPTGPR119MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600731-B2 | Isoxazolo[5,4-H]quinazoline compounds as protein kinase inhibitors | Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. (CN) | 2026-04-14 | — | — | US | disclosed |
| EP-4695405-A2 | SMALL-MOLECULE REGULATED ALTERNATIVE SPLICING | Rgenta Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4658658-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2025-12-10 | — | — | EP | disclosed |
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | SIGNAL PHARMACEUTICALS, LLC | 2025-09-04 | — | — | US | disclosed |
| EP-4605088-A1 | MOLECULAR GLUE DEGRADER COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CELGENE CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| CN-113929675-B | Synthesis method of piperaquine Bai Xili | 苏州特瑞药业股份有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-12215105-B2 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4479380-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | Accent Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024256569-A1 | NOVEL CDK DEGRADERS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2024-12-19 | — | — | WO | disclosed |
| US-11505548-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CELGENE CORPORATION (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220363690-A1 | ISOXAZOLO[5,4-H]QUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. (CN) | 2022-11-17 | — | — | US | disclosed |
| WO-2022174253-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-4027995-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| WO-2022113003-A1 | CDK INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| EP-3997088-A1 | DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS | Aucentra Therapeutics Pty Ltd (AU) | 2022-05-18 | — | — | EP | disclosed |
| WO-2022091001-A1 | PROCESS FOR PREPARATION OF PALBOCICLIB | PFIZER IRELAND PHARMACEUTICALS (IE) | 2022-05-05 | — | — | WO | disclosed |
| EP-3434676-B1 | SUBSTITUTED PYRROLOPYRIMIDINE CDK INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-03-09 | — | — | EP | disclosed |
| EP-3959207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2022-03-02 | — | — | EP | disclosed |
| WO-2022019597-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | 주식회사 유빅스테라퓨틱스 | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, HAX1, HRH4 | MAPT 448/4885ALDH1A1 1513/4885LMNA 1044/4885 |
| US-11505548-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CYP8B1, HAX1, HRH4 | MAPT 448/4885ALDH1A1 1513/4885LMNA 1044/4885 |
| US-20220363690-A1 | ISOXAZOLO[5,4-H]QUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | CDK2, CDKL1, CDK7 | MAPT 3727/4885ALDH1A1 3592/4885LMNA 2622/4885 |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CYP8B1, HAX1, HRH4 | MAPT 448/4885ALDH1A1 1513/4885LMNA 1044/4885 |
| US-12600731-B2 | Isoxazolo[5,4-H]quinazoline compounds as protein kinase inhibitors | CCNO, CDK7, CDK6 | MAPT 4596/4885ALDH1A1 3409/4885LMNA 2736/4885 |
| US-12215105-B2 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | MAPT 3895/4885ALDH1A1 4740/4885LMNA 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.